# Study Of Safety And Tolerability Of GW786034 Given With Lapatinib In Cancer Patients

> **NCT00158782** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 75 (actual)

## Conditions studied

- Carcinoma, Renal Cell

## Interventions

- **DRUG:** GW786034
- **DRUG:** lapatinib

## Key facts

- **NCT ID:** NCT00158782
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-09-28
- **Primary completion:** 2007-08-21
- **Final completion:** 2007-08-21
- **Target enrollment:** 75 (ACTUAL)
- **Last updated:** 2017-11-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00158782

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00158782, "Study Of Safety And Tolerability Of GW786034 Given With Lapatinib In Cancer Patients". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00158782. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*